Business Wire

Reflow Medical Expands Global Reach with New European Subsidiary

7.3.2025 15:46:00 EET | Business Wire | Press release

Share

Reflow Medical, Inc., a leading developer of innovative medical devices for complex cardiovascular disease, has announced the opening of its European subsidiary in Landsberg am Lech, Germany. This strategic expansion strengthens the company’s international presence and enhances its ability to serve markets outside the United States.

Reflow Medical Europe GmbH is led by Senior Vice President and General Manager Knut Sauerteig. Under his leadership, the European subsidiary will focus on establishing direct sales channels and forging strategic distribution partnerships across multiple regions.

“Expanding into markets outside the United States marks a significant milestone for our company,” said Isa Rizk, Co-Founder and CEO of Reflow Medical. “This presence allows us to better address the needs of international markets by providing direct sales solutions and forming key distribution collaborations. Our goal is to deliver breakthrough technologies that support physicians and improve patient outcomes worldwide.”

John Fulkerson, Co-Founder and COO of Reflow Medical, emphasized the operational benefits of the new European base: “This expansion enables us to streamline product distribution, significantly reducing delivery times and enhancing service reliability. These factors are critical to maintaining high quality standards in the medical device industry.”

Sauerteig highlighted the company’s broader ambitions: “Our team is committed to driving growth across Europe, the Middle East, Africa, Latin America, and the Asia-Pacific region. In the coming years, we will continue to expand our presence by building direct sales organizations and strengthening distribution partnerships to better serve the needs of healthcare providers and patients.”

The launch of Reflow Medical Europe GmbH underscores the company’s dedication to advancing cardiovascular care on a global scale. By expanding its reach and enhancing service capabilities, Reflow Medical is well-positioned to deliver innovative medical solutions to a broader international audience.

About Reflow Medical, Inc.

Reflow Medical is a global company working with leading physicians to develop innovative technologies designed to fill unmet clinical needs in the treatment of complex cardiovascular disease. The portfolio consists of the CoraCatheters™ line of innovative coronary microcatheters to cross complex lesions (available in the U.S. only) as well as unique peripheral catheters, including the Wingman™ CTO Crossing Catheter, the Spex® and Spex® LP Shapeable Support Microcatheters, and the Spur® Peripheral Retrievable Scaffold System. The Spur has earned the CE Mark for the treatment of restenotic lesions in below-the-knee arteries, when used in conjunction with a commercially available drug-coated balloon. The Spur is an investigational device in the US. Reflow Medical is headquartered in San Clemente, California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250306101322/en/

Contacts

Jennifer Carlyle
jcarlyle@reflowmedical.com
949-481-0399

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 01:05:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs, including the Phase 3 KRAS G12D and TGFβR2×PD-1 studies already underway.” Details on rapid oral presentations at ESMO include: INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Monotherapy or in Combination with Cetuximab (Cetux) in Patients (pts) with Advanced/Metastatic Colorectal Cancer (CRC) Session:

DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future18.10.2026 21:35:00 EEST | Press release

The Digital Cooperation Organization (DCO) launched the second edition of the Digital Prosperity Awards (DPA), opening applications and nominations for eligible public-sector, private-sector and civil-society digital solutions across Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261018682401/en/ DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future (Photo: AETOSWire) The Awards recognize technology-driven solutions, initiatives and contributions delivering measurable socioeconomic impact, accelerating digital transformation and advancing an inclusive, sustainable and prosperous digital economy. The inaugural edition honored seven winners in February 2025. Ms. Deemah AlYahya, Secretary-General of the DCO, said: “A prosperous digital future is taking shape today through the vision, commitment and creativity of governments, innovators, organization

TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal16.10.2026 17:00:00 EEST | Press release

TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device. Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams: Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts. Developers pick a model and OS version, or let the cloud assign any available device. A live view of the device. The real device's screen opens in its own window on the developer's lapto

Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World16.10.2026 17:00:00 EEST | Press release

Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016490320/en/ Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World (Photo: AETOSWire) It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment. The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating oppor

METI and GX Acceleration Agency will hold GGX Finance Summit 202616.10.2026 16:00:00 EEST | Press release

On Monday, October 26th, the Ministry of Economy, Trade and Industry (METI) and GX Acceleration Agency will hold the GGX (Global GX) Finance Summit at Tokyo Prince Hotel and online. The Summit will advance discussions on transition finance, industry decarbonization, and the role of business and finance in driving decarbonization. It will also promote cooperation among government, industry, and the financial sector, and lead international rulemaking toward achieving both emission reductions and economic growth. Outline of GGX Finance Summit Date: October 26th, 2026 10:00 - 16:20 (JST, GMT+9:00) Venue: Tokyo Prince Hotel (Tokyo) (3-3-1 Shiba-Koen, Minato-ku, Tokyo 105-8560, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: GX Future Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation) Press Registration Please complete your registration by accessing the official

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye